Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370. / Jepps, Thomas Andrew; Bentzen, B H; Stott, J B; Povstyan, O V; Sivaloganathan, K; Dalby-Brown, W; Greenwood, I A.

In: British Journal of Pharmacology, Vol. 171, No. 19, 09.06.2014, p. 4413-4424.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Jepps, TA, Bentzen, BH, Stott, JB, Povstyan, OV, Sivaloganathan, K, Dalby-Brown, W & Greenwood, IA 2014, 'Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370', British Journal of Pharmacology, vol. 171, no. 19, pp. 4413-4424. https://doi.org/10.1111/bph.12805

APA

Jepps, T. A., Bentzen, B. H., Stott, J. B., Povstyan, O. V., Sivaloganathan, K., Dalby-Brown, W., & Greenwood, I. A. (2014). Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370. British Journal of Pharmacology, 171(19), 4413-4424. https://doi.org/10.1111/bph.12805

Vancouver

Jepps TA, Bentzen BH, Stott JB, Povstyan OV, Sivaloganathan K, Dalby-Brown W et al. Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370. British Journal of Pharmacology. 2014 Jun 9;171(19):4413-4424. https://doi.org/10.1111/bph.12805

Author

Jepps, Thomas Andrew ; Bentzen, B H ; Stott, J B ; Povstyan, O V ; Sivaloganathan, K ; Dalby-Brown, W ; Greenwood, I A. / Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370. In: British Journal of Pharmacology. 2014 ; Vol. 171, No. 19. pp. 4413-4424.

Bibtex

@article{f1435fee37e84607b43970a7a0df60d3,
title = "Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370",
abstract = "BACKGROUND AND PURPOSE: The KCNQ encoded voltage-gated potassium channel family (Kv7.1-Kv7.5) are established regulators of smooth muscle contractility, where Kv7.4 and Kv7.5 predominate. Various Kv7.2-Kv7.5 channel enhancers have been developed that have been shown to cause a vasorelaxation in both rodent and human blood vessels. Recently, two novel Kv7 channel enhancers have been identified, ML213 and NS15370, that show increased potency, particularly on Kv7.4 channels. The aim of this study was to characterise the effects of these novel enhancers in different rat blood vessels and compare them to Kv7 enhancers (S-1, BMS-204352, retigabine) described previously. We also sought to determine the binding sites of the new Kv7 enhancers.KEY RESULTS: Both ML213 and NS15370 relaxed segments of rat thoracic aorta, renal artery and mesenteric artery in a concentration-dependent manner. In the mesenteric artery ML213 and NS15370 displayed EC50 's of 0.74 μM and 0.026 μM, respectively, which were far lower than other Kv7 enhancers tested. Current-clamp experiments revealed both novel enhancers at low concentrations caused significant hyperpolarisation in mesenteric artery smooth muscle cells. In addition, we determined that the stimulatory effect of these enhancers relied on a tryptophan residue located in the S5 domain, the same binding site for the other Kv7 enhancers tested in this study.CONCLUSIONS AND IMPLICATIONS: In conclusion, this study identifies and characterises ML213 and NS15370 as potent vasorelaxants in different blood vessels, thereby highlighting these new compounds as potential therapeutics for various smooth muscle disorders.",
author = "Jepps, {Thomas Andrew} and Bentzen, {B H} and Stott, {J B} and Povstyan, {O V} and K Sivaloganathan and W Dalby-Brown and Greenwood, {I A}",
note = "This article is protected by copyright. All rights reserved.",
year = "2014",
month = "6",
day = "9",
doi = "10.1111/bph.12805",
language = "English",
volume = "171",
pages = "4413--4424",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley",
number = "19",

}

RIS

TY - JOUR

T1 - Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370

AU - Jepps, Thomas Andrew

AU - Bentzen, B H

AU - Stott, J B

AU - Povstyan, O V

AU - Sivaloganathan, K

AU - Dalby-Brown, W

AU - Greenwood, I A

N1 - This article is protected by copyright. All rights reserved.

PY - 2014/6/9

Y1 - 2014/6/9

N2 - BACKGROUND AND PURPOSE: The KCNQ encoded voltage-gated potassium channel family (Kv7.1-Kv7.5) are established regulators of smooth muscle contractility, where Kv7.4 and Kv7.5 predominate. Various Kv7.2-Kv7.5 channel enhancers have been developed that have been shown to cause a vasorelaxation in both rodent and human blood vessels. Recently, two novel Kv7 channel enhancers have been identified, ML213 and NS15370, that show increased potency, particularly on Kv7.4 channels. The aim of this study was to characterise the effects of these novel enhancers in different rat blood vessels and compare them to Kv7 enhancers (S-1, BMS-204352, retigabine) described previously. We also sought to determine the binding sites of the new Kv7 enhancers.KEY RESULTS: Both ML213 and NS15370 relaxed segments of rat thoracic aorta, renal artery and mesenteric artery in a concentration-dependent manner. In the mesenteric artery ML213 and NS15370 displayed EC50 's of 0.74 μM and 0.026 μM, respectively, which were far lower than other Kv7 enhancers tested. Current-clamp experiments revealed both novel enhancers at low concentrations caused significant hyperpolarisation in mesenteric artery smooth muscle cells. In addition, we determined that the stimulatory effect of these enhancers relied on a tryptophan residue located in the S5 domain, the same binding site for the other Kv7 enhancers tested in this study.CONCLUSIONS AND IMPLICATIONS: In conclusion, this study identifies and characterises ML213 and NS15370 as potent vasorelaxants in different blood vessels, thereby highlighting these new compounds as potential therapeutics for various smooth muscle disorders.

AB - BACKGROUND AND PURPOSE: The KCNQ encoded voltage-gated potassium channel family (Kv7.1-Kv7.5) are established regulators of smooth muscle contractility, where Kv7.4 and Kv7.5 predominate. Various Kv7.2-Kv7.5 channel enhancers have been developed that have been shown to cause a vasorelaxation in both rodent and human blood vessels. Recently, two novel Kv7 channel enhancers have been identified, ML213 and NS15370, that show increased potency, particularly on Kv7.4 channels. The aim of this study was to characterise the effects of these novel enhancers in different rat blood vessels and compare them to Kv7 enhancers (S-1, BMS-204352, retigabine) described previously. We also sought to determine the binding sites of the new Kv7 enhancers.KEY RESULTS: Both ML213 and NS15370 relaxed segments of rat thoracic aorta, renal artery and mesenteric artery in a concentration-dependent manner. In the mesenteric artery ML213 and NS15370 displayed EC50 's of 0.74 μM and 0.026 μM, respectively, which were far lower than other Kv7 enhancers tested. Current-clamp experiments revealed both novel enhancers at low concentrations caused significant hyperpolarisation in mesenteric artery smooth muscle cells. In addition, we determined that the stimulatory effect of these enhancers relied on a tryptophan residue located in the S5 domain, the same binding site for the other Kv7 enhancers tested in this study.CONCLUSIONS AND IMPLICATIONS: In conclusion, this study identifies and characterises ML213 and NS15370 as potent vasorelaxants in different blood vessels, thereby highlighting these new compounds as potential therapeutics for various smooth muscle disorders.

U2 - 10.1111/bph.12805

DO - 10.1111/bph.12805

M3 - Journal article

VL - 171

SP - 4413

EP - 4424

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 19

ER -

ID: 114785860